NetScientific PLC Wanda and Dignity Health launch OncoVerse platform (3883Q)
29 Fevereiro 2016 - 4:01AM
UK Regulatory
TIDMNSCI
RNS Number : 3883Q
NetScientific PLC
29 February 2016
NetScientific plc
Wanda(TM) partners with leading US Hospital Group Dignity
Health(TM) to launch oncology decision support software platform -
OncoVerse(TM)
London, UK - 29 February 2016 - NetScientific plc
("NetScientific" or the "Group", AIM: NSCI), the transatlantic
biomedical and healthcare technology group, announces that its
operating subsidiary, Wanda, has signed a collaborative deal with
one of the US's biggest hospital groups, Dignity Health, to launch
OncoVerse, a digital health oncology care platform.
OncoVerse is a software platform designed to enable a patient's
care team to collaborate in real-time, allowing clinicians across
all disciplines to work together to determine the most effective
treatment plan for cancer patients. Dignity Health engaged Wanda to
develop the software due to the Company's proven track record in
developing effective platforms that support informed treatment
decisions. The software will also help to reduce administrative
costs associated with high quality cancer care.
Dignity Health is a network of nearly 9,000 physicians and more
than 400 care centers, including hospitals and primary care clinics
spanning 21 US states. The OncoVerse platform will support Dignity
Health's physicians and healthcare professionals to enable them to
make informed decisions on the treatment of cancer patients. It
will also enable Dignity Health to expand the geographic reach of
its clinical decision-making support system to reach the most rural
and remote areas - allowing all patients to benefit from insights
previously only shared at large medical centers.
Wanda and Dignity Health are shareholders in Oncoverse LLC, a
San Francisco based digital health company, and the creator of the
OncoVerse(TM) software platform. Wanda and Dignity Health will
jointly market the Oncoverse platform to other oncology programs
across the US later in 2016 to earn revenues through uptake of the
platform. The relationship with Dignity Health will also allow for
cross-marketing of existing and future Wanda products.
Facilitating individualized cancer decision support is becoming
increasingly important as cancer therapies advance. Wanda's core
technology aims to improve the efficiency and effectiveness of the
management of chronic conditions.
Commenting on the news, NetScientific's Chief Executive Officer,
Francois R. Martelet said: "Wanda is the Group's lead subsidiary in
our digital health franchise. The launch of Oncoverse with Dignity
Health, and its huge US network, is a significant milestone for the
Company and further endorses its core technology. This deal marks
the second partnership that Wanda has secured with a leading US
healthcare group since the start of 2016 as it continues to develop
more platforms to better manage chronic conditions."
-ends-
Contact Details
NetScientific Tel: +44 (0)20
François R. Martelet, 3514 1800
M.D., CEO
Mark Nanovich, Interim
CFO
Tel: +44 (0)20
Investec (NOMAD and 7597 4000
broker)
Gary Clarence / Daniel
Adams
Tel: +44 (0)20
Instinctif Partners 7457 2020 Email:
Melanie Toyne-Sewell netscientific@instinctif.com
/ Jayne Crook / Rosanna
Forrest
About OncoVerse
San Francisco-based Oncoverse, LLC is a digital health care
platform company which enables health care professionals to
collaborate on cancer patient care decisions, and to monitor the
progress of patient therapies. Oncoverse(TM) has the potential to
transform cancer care delivery by establishing a common platform
for all cancer patients to access the best medical expertise, while
at the same time providing physicians with an opportunity to
present their oncology cases for evidence-based peer collaboration,
review, treatment recommendations and second opinions that are
available 24/7 from any computer or other web-enabled device.
About Dignity Health
Dignity Health, one of the nation's largest health care systems,
is a 21-state network of nearly 9,000 physicians, 59,000 employees,
and more than 400 care centers, including hospitals, urgent and
occupational care, imaging centers, home health, and primary care
clinics. Headquartered in San Francisco, Dignity Health is
dedicated to providing compassionate, high-quality and affordable
patient-centered care with special attention to the poor and
underserved. In FY15, Dignity Health provided $1.7 billion in
charitable care and services. For more information, please visit
our website at www.dignityhealth.org. You can also follow us on
Twitter and Facebook.
About Wanda
San Francisco-based Wanda is dedicated to advancing the
effectiveness and efficiency of medicine by using machine learning
in place of conventional technologies and by enabling clinicians to
make more informed care decisions. Wanda recognizes that remote
monitoring and algorithms cannot save lives or reduce
hospitalizations unless the individual and their caregivers are
promptly informed and highly engaged. Through the collaboration of
data science and applied medical research, Wanda has proven that
its inline analytics predict preventable events much better than
conventional methods. Wanda serves as a diligent companion,
providing encouragement and intelligent visual guidance that
simplifies and improves lives, while simultaneously helping
organizations reduce their care delivery costs. Wanda is a
NetScientific company. More information about Wanda can be found
HERE.
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment.
For more information, please visit the website at
www.netscientific.net.
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRZMGZZMRNGVZZ
(END) Dow Jones Newswires
February 29, 2016 02:01 ET (07:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024